RenovoRx Inc. (RNXT)
1.00
0.04 (4.17%)
At close: Apr 02, 2025, 3:50 PM
4.17% (1D)
| Bid | 0.91 |
| Market Cap | 35.59M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | n/a |
| EPS (ttm) | -0.58 |
| PE Ratio (ttm) | -1.73 |
| Forward PE | -3.04 |
| Analyst | Strong Buy |
| Ask | 1.04 |
| Volume | 44,172 |
| Avg. Volume (20D) | 138,953 |
| Open | 0.92 |
| Previous Close | 0.96 |
| Day's Range | 0.92 - 1.01 |
| 52-Week Range | 0.77 - 1.69 |
| Beta | 1.15 |
About RNXT
RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California....
Industry Biotechnology
Sector Healthcare
IPO Date Aug 26, 2021
Employees 8
Stock Exchange NASDAQ
Ticker Symbol RNXT
Website https://renovorx.com
Analyst Forecast
According to 2 analyst ratings, the average rating for RNXT stock is "Strong Buy." The 12-month stock price forecast is $6, which is an increase of 499.52% from the latest price.
Stock ForecastsNext Earnings Release
RenovoRx Inc. is scheduled to release its earnings on Apr 15, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-20.55%
RenovoRx shares are trading lower after the compan...
Unlock content with
Pro Subscription
1 month ago
-2.01%
RenovoRx shares are trading lower after the company announced a proposed public offering.
